# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Topline data now projected in early Q4 2024 Rohit Loomba, MD, MHSc to serve as Principal InvestigatorSOUTH SAN FRANCISCO, Calif...
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of...
Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does ...
https://www.fpds.gov/common/jsp/LaunchWebPage.jsp?command=execute&requestid=172813877&version=1.5
Aligos Therapeutics, Inc. (NASDAQ:ALGS, ", Aligos", )))), a clinical stage biopharmaceutical company focused on develop...